Altitude Life Science Ventures

Single-letter gene editing startup Beam Therapeutics raises $135M Series B round

The company is developing means using CRISPR/Cas9 to edit genomes at the single-letter level, as opposed to the DNA- and RNA-cutting method usually employed.